In line, AMO-1 MM cell line derived clones with bi-allelic TP53 inactivation out-competed AMO-1 clones with mono-allelic TP53 aberrations in comparative in vitro studies indicating a selection advantage of TP53 double-hit myeloma cell clones (187, 189). The gene discussed is TP53; the disease is plasma cell myeloma.